deltatrials
Terminated PHASE3 NCT00517192

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

A Prospective, Randomized, Open-labelled, Multi-centre Trial Comparing the Safety and Efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to That of Prezista® (Darunavir, DRV/r) in Three-class (NRTI, NNRTI, and PI) Treatment-experienced Patients With Resistance to More Than One PI. POTENT: PrOspecTive EvaluatioN of Tipranavir vs. Darunavir in Treatment Experienced Patients

Sponsor: Boehringer Ingelheim

Conditions HIV Infections
Interventions Darunavir Ritonavir Tipranavir
Updated 6 times since 2017 Last updated: Apr 25, 2014 Started: Sep 30, 2007 Primary completion: Sep 30, 2008

A PHASE3 clinical study on HIV Infections, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 6 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amadora, Portugal, Antella (fi), Italy, Athens, Greece, Bangkok, Thailand, Bangkok Noi, Thailand, Barcelona, Spain, Berlin, Germany, Beverly Hills, United States, Bondy, France, Brescia, Italy and 34 more location s